LUM001 (Maralixibat)
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Familial Intrahepatic Cholestasis (PFIC)
Conditions
Progressive Familial Intrahepatic Cholestasis (PFIC)
Trial Timeline
Mar 1, 2014 → May 8, 2020
NCT ID
NCT02057718About LUM001 (Maralixibat)
LUM001 (Maralixibat) is a phase 2 stage product being developed by Mirum Pharmaceuticals for Progressive Familial Intrahepatic Cholestasis (PFIC). The current trial status is completed. This product is registered under clinical trial identifier NCT02057718. Target conditions include Progressive Familial Intrahepatic Cholestasis (PFIC).
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02117713 | Phase 2 | Completed |
| NCT02057718 | Phase 2 | Completed |
| NCT02047318 | Phase 2 | Completed |
Competing Products
20 competing products in Progressive Familial Intrahepatic Cholestasis (PFIC)